
Jan 23 (Reuters) - Vigil Neuroscience Inc VIGL.O:
VIGIL NEUROSCIENCE REPORTS POSITIVE DATA FROM ITS PHASE 1 CLINICAL TRIAL EVALUATING VG-3927 FOR THE POTENTIAL TREATMENT OF ALZHEIMER’S DISEASE
VIGIL NEUROSCIENCE INC - VG-3927 TO ADVANCE TO PHASE 2 TRIAL IN Q3 2025
VIGIL NEUROSCIENCE INC - VG-3927 ACHIEVED UP TO 50% REDUCTION OF STREM2 IN CSF
VIGIL NEUROSCIENCE INC - VG-3927 SHOWED FAVORABLE SAFETY AND TOLERABILITY PROFILE
Source text: ID:nGNXqgh0d
Further company coverage: VIGL.O